Anti-CD3 x Anti-PSCA Bispecific Antibody (IgG-IgG) (BSIG-H275)

Anti-CD3 x Anti-PSCA Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD3 and anti-PSCA parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy.

Datasheet

Specifications

Targets

CD3 & PSCA

Type

IgG-IgG

Species Reactivity

Human

Target 1

CD3

Host Animal 1

Human

Target 2

PSCA

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Prostate cancer

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

PSCA

Gene ID

8000

UniProt ID

D3DWI6

Alternative Names

PSCA; prostate stem cell antigen; PRO232

Our services and products are only for lab research, not for any diagnostic or therapeutic use.

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

Germany
Heidenkampsweg 58, 20097 Hamburg, Germany
Email:

UK
167-169 Great Portland Street, 5th Floor, London, W1W 5PE
Tel: 44-207-097-1828
Email: